Celcuity (CELC) Projected to Post Earnings on Thursday

Celcuity (NASDAQ:CELC) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 14th. Analysts expect Celcuity to post earnings of ($0.94) per share for the quarter.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Stock Performance

Shares of NASDAQ CELC opened at $50.06 on Wednesday. The company has a current ratio of 6.61, a quick ratio of 6.61 and a debt-to-equity ratio of 1.14. Celcuity has a 12 month low of $7.57 and a 12 month high of $50.33. The company has a 50 day simple moving average of $20.06 and a two-hundred day simple moving average of $13.95. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -16.52 and a beta of 0.68.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. HC Wainwright lifted their price objective on shares of Celcuity from $27.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, July 28th. Stifel Nicolaus began coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a “buy” rating and a $30.00 price objective for the company. Leerink Partners boosted their target price on shares of Celcuity from $28.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, July 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $29.00 target price on shares of Celcuity in a research note on Monday, July 28th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Celcuity has a consensus rating of “Buy” and an average price target of $39.20.

Insider Activity

In related news, Director David Dalvey sold 100,000 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the transaction, the director directly owned 125,000 shares in the company, valued at $5,497,500. The trade was a 44.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 15.78% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Celcuity

Large investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the period. Creative Planning acquired a new position in Celcuity during the second quarter worth $177,000. Finally, XTX Topco Ltd acquired a new position in Celcuity during the second quarter worth $169,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.